<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="result" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1004" relname="span">Epilepsy is a disorder in the central nervous system</segment>
<segment id="3" parent="2" relname="restatement">( CNS )</segment>
<segment id="4" parent="1005" relname="span">that is characterized by an increase in the number of electrical impulses</segment>
<segment id="5" parent="4" relname="elaboration">that occurs in one focal locus of the brain and/or the entire brain ,</segment>
<segment id="6" parent="1003" relname="elaboration">resulting in partial or generalized seizures .</segment>
<segment id="7" parent="1006" relname="joint">The administration of antiepileptic drugs is mostly done via the oral or intravenous routes .</segment>
<segment id="8" parent="1007" relname="joint">Drug resistance at the late stage of therapy develops in about 40 % of patients .</segment>
<segment id="9" parent="1009" relname="span">Drug resistance leads to uncontrolled seizures , a higher risk of brain damage , and increased mortality rates .</segment>
<segment id="10" parent="1010" relname="joint">Patients with epilepsy suffer from emotional and behavioral changes , seizures , convulsions , muscular spasms , depression and , in some cases , unconsciousness .</segment>
<segment id="11" parent="1012" relname="span">Drugs</segment>
<segment id="12" parent="11" relname="elaboration">used for the treatment of epilepsy have poor bioavailability</segment>
<segment id="13" parent="1011" relname="joint">and eventually become ineffective over the course of treatment due to drug resistance .</segment>
<segment id="14" parent="1014" relname="span">Epilepsy treatment is often complicated due to the poor release of the drug through the adjunctive blood – brain barrier ,</segment>
<segment id="15" parent="14" relname="elaboration">which may be overcome by the preparation of the drug as solid lipid nanoparticles .</segment>
<segment id="16" parent="1017" relname="span">The ideal delivery systems of antiepileptic drugs are the ones</segment>
<segment id="17" parent="16" relname="elaboration">which provide localized and controlled drug release to targeted sites in the brain ,</segment>
<segment id="18" parent="1018" relname="joint">which helps to reduce drug-associated toxicities</segment>
<segment id="19" parent="1018" relname="joint">and enhances the efficacy of the drug .</segment>
<segment id="20" parent="1022" relname="span">Carbamazepine</segment>
<segment id="21" parent="20" relname="restatement">( CBZ )</segment>
<segment id="22" parent="1021" relname="same_unit">is an antiepileptic drug with a narrow therapeutic index ,</segment>
<segment id="23" parent="1023" relname="span">and it is poorly absorbed</segment>
<segment id="24" parent="23" relname="circumstance">when taken by the oral route .</segment>
<segment id="25" parent="1025" relname="joint">Its oral bioavailability is 75 % ,</segment>
<segment id="26" parent="1025" relname="joint">and its maximum achieved plasma concentration is about 4 – 8 h after administration .</segment>
<segment id="27" parent="1027" relname="span">Carbamazepine acts through the inactivation of sodium channels ,</segment>
<segment id="28" parent="27" relname="result">making brain cells less excitable .</segment>
<segment id="29" parent="1030" relname="span">Solid lipid nanoparticles</segment>
<segment id="30" parent="29" relname="restatement">( SLNs )</segment>
<segment id="31" parent="1029" relname="same_unit">are considered an alternative to colloidal systems like liposome , noisome and polymeric nanoparticles .</segment>
<segment id="32" parent="1032" relname="span">SLNs consist of solid lipids ,</segment>
<segment id="33" parent="1033" relname="span">which act as a stabilizer</segment>
<segment id="34" parent="33" relname="circumstance">when dispersed in water in the presence of a surfactant .</segment>
<segment id="35" parent="1036" relname="span">SLN is characterized by its small size</segment>
<segment id="36" parent="35" relname="elaboration">( nano range ) , large surface area , and high drug loading capacity .</segment>
<segment id="37" parent="1037" relname="joint">In addition , it improves drug stability</segment>
<segment id="38" parent="1038" relname="span">and has the ability</segment>
<segment id="39" parent="38" relname="purpose">to improve the oral bioavailability of poorly water-soluble drugs .</segment>
<segment id="40" parent="1040" relname="span">Gangurde and Kumar prepared lamotrigine solid lipid nanoparticles with a high efficacy for treatment of epilepsy .</segment>
<segment id="41" parent="1042" relname="span">Nair et al. prepared carbamazepine solid lipid nanoparticles</segment>
<segment id="42" parent="41" relname="purpose">to improve its therapeutic effect .</segment>
<segment id="43" parent="1043" relname="span">Kumar et al. prepared solid lipid nanoparticles of methylthioadenosine for the management of neurological conditions via oral delivery .</segment>
<segment id="44" parent="1045" relname="span">The objective of the current study was to prepare carbamazepine solid lipid nanoparticles</segment>
<segment id="45" parent="44" relname="restatement">( CBZ-SLNs )</segment>
<segment id="46" parent="1044" relname="same_unit">as a novel and alternative method for other colloidal dispersion carriers .</segment>
<segment id="47" parent="1040" relname="elaboration">The study aimed to prepare CBZ-SLNs with high entrapment efficiency % , small particle size , and high anticonvulsant activity compared to free CBZ .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="span"/>
<group id="1003" type="span" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="span"/>
<group id="1005" type="span" parent="1004" relname="elaboration"/>
<group id="1006" type="multinuc" parent="1002" relname="elaboration"/>
<group id="1007" type="multinuc" parent="1006" relname="joint"/>
<group id="1008" type="multinuc" parent="1007" relname="joint"/>
<group id="1009" type="span" parent="1008" relname="joint"/>
<group id="1010" type="multinuc" parent="9" relname="elaboration"/>
<group id="1011" type="multinuc" parent="1010" relname="joint"/>
<group id="1012" type="span" parent="1011" relname="joint"/>
<group id="1013" type="span" parent="1008" relname="joint"/>
<group id="1014" type="span" parent="1013" relname="span"/>
<group id="1015" type="multinuc" parent="1014" relname="elaboration"/>
<group id="1016" type="span" parent="1015" relname="joint"/>
<group id="1017" type="span" parent="1016" relname="span"/>
<group id="1018" type="multinuc" parent="1017" relname="elaboration"/>
<group id="1019" type="multinuc" parent="1015" relname="joint"/>
<group id="1020" type="multinuc" parent="1019" relname="joint"/>
<group id="1021" type="multinuc" parent="1020" relname="joint"/>
<group id="1022" type="span" parent="1021" relname="same_unit"/>
<group id="1023" type="span" parent="1020" relname="joint"/>
<group id="1024" type="multinuc" parent="1019" relname="joint"/>
<group id="1025" type="multinuc" parent="1024" relname="joint"/>
<group id="1026" type="multinuc" parent="1024" relname="joint"/>
<group id="1027" type="span" parent="1026" relname="joint"/>
<group id="1028" type="multinuc" parent="1026" relname="joint"/>
<group id="1029" type="multinuc" parent="1028" relname="joint"/>
<group id="1030" type="span" parent="1029" relname="same_unit"/>
<group id="1031" type="multinuc" parent="1028" relname="joint"/>
<group id="1032" type="span" parent="1031" relname="joint"/>
<group id="1033" type="span" parent="32" relname="elaboration"/>
<group id="1034" type="multinuc" parent="1031" relname="joint"/>
<group id="1035" type="multinuc" parent="1034" relname="joint"/>
<group id="1036" type="span" parent="1035" relname="joint"/>
<group id="1037" type="multinuc" parent="1035" relname="joint"/>
<group id="1038" type="span" parent="1037" relname="joint"/>
<group id="1039" type="span" parent="1034" relname="joint"/>
<group id="1040" type="span" parent="1039" relname="span"/>
<group id="1041" type="multinuc" parent="40" relname="elaboration"/>
<group id="1042" type="span" parent="1041" relname="joint"/>
<group id="1043" type="span" parent="1041" relname="joint"/>
<group id="1044" type="multinuc" parent="43" relname="elaboration"/>
<group id="1045" type="span" parent="1044" relname="same_unit"/>
	</body>
</rst>
